Moonriver (MOVR) sees 71.3% volatility in 24 hours: Surge in trading volume and whale accumulation drive movement
Bitget Pulse2026/04/18 16:02Volatility Overview
In the past 24 hours, MOVR prices rebounded from a low of $2.210 to a high of $3.786, currently quoted at $2.318, with a fluctuation amplitude of 71.3%. Trading volume surged to approximately $82.43 million, rising by more than 5000% from previous levels, showing clear signs of capital inflows.
Brief Analysis of the Anomaly Causes
- Explosive growth in trading volume: Within 24 hours, trading volume soared by 5100% to $130 million, triggering a liquidity breakthrough and buying pressure.
- Active whale accumulation: On-chain data shows significant purchases by large holders, driving vertical price escalation.
- Overall altcoin rebound: MOVR led the Polkadot ecosystem (such as KSM), with gains exceeding 200%, integrating into a broader altcoin season trend.
Market Opinions and Outlook
Community sentiment is running high, with discussions on X platform focused on gains of 150%-200%. Short-term targets are projected at $4-5, but with RSI reaching 97 signaling overbought conditions, mainstream views warn of potential retracement risk to the $2.5 support level and advise caution in chasing highs.
Note: This analysis is automatically generated by AI based on public data and on-chain monitoring and is for informational reference only.Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
RBA set to hike interest rate to 4.60% in September as inflation remains elevated
AstraZeneca invests $2 billion in Summit, optimistic about Akeso's Ivose
This 18.6% premium subscription is not only a substantial endorsement, but both parties will also deeply collaborate on the joint development of combination therapies such as ADCs. The core of this deal is Akeso's Ivonescimab—the world’s first PD-1/VEGF bispecific antibody, and so far the only drug to have surpassed "K-drug" in head-to-head trials on both PFS and OS endpoints. The median OS reached 30.8 months, compared to 22.6 months for "K-drug", representing a 27% reduction in risk of death.
AMD (AMD.US) Surpasses $1 Trillion Market Cap and Begins Competing for "Computing Power Definition Rights"! Officially Announces $8.2 Billion Acquisition of Fei-Fei Li's World Labs
AMD has agreed to acquire World Labs for $8.2 billion, thereby gaining access to the artificial intelligence startup founded by industry pioneer and researcher Fei-Fei Li. This acquisition is expected to help AMD plan its future hardware launches by bringing in a team of top researchers and their models, as well as deep insights into trends in the field of artificial intelligence.
Crypto prices
More
